Defining the Place of Adjuvant Chemotherapy and Radiation for High-Risk Endometrial Cancer From Recent Randomized Clinical Trials: Some Answers, More Questions

Endometrial carcinoma is the most common gynecologic malignancy. Most patients present with early stage disease, but in about 10% to 15% of all new cases of endometrial cancer, disease is found outside the uterus at diagnosis. These patients account for more than 50% of all uterine cancer–related deaths. They are treated with adjuvant chemotherapy (CT) and/or radiation therapy (RT), although we do not know the true impact of adjuvant treatment on survival (1). This issue's Oncology Scan covers 3 recently presented or published prospective trials—Gynecology Oncology Group (GOG)-258 (2), GOG-249 (3), and Postoperative Radiation Therapy in Endometrial Carcinoma (PORTEC-3) (4)—and a National Cancer Database (NCDB) (5) analysis that tried to define optimal adjuvant treatment for high- or high-intermediate-risk endometrial cancer.

https://ift.tt/2QtLGiQ